Antibodies have re-shaped biomedical researches since their discovery. From research tools to therapeutics and diagnostics, antibodies are indispensable in finding cures for a host of different diseases. In recent years, antibody-based therapeutics have dramatically changed the way we treat diseases, especially in oncology. The recent introduction of platforms has further advanced how antibodies are being used.

Stem cells have attracted a great deal of deserved attention due to their lineage-independent characteristics. In other words, they have the potential to be differentiated into a countless number of cell types. Adult stem cells, otherwise known as inducible pluripotent stem cells (iPSCs), are particularly favorable as research tools because they are derived from a patient’s somatic cells such as blood, skin or muscle.

As a relatively new means of conducting research in the life sciences, RWE, or real-world evidence, is data that comes from “real world settings” such as a clinical practice. Studies driven by real world evidence, or real-world data (RWD), can utilize data from medical records or claims databases, be conducted prospectively in observational studies or adhere to a mixed, hybrid-design approach.

Two global forces are at odds today – the push for “greener” processes and the demand for lower prices for prescription drugs and materials. Governments and corporations across the globe are adopting policy initiatives and driving scientific innovations to promote sustainable technologies, resulting in an explosion of discoveries based on both chemical- and biocatalytic transformations.

AI’s use in drug discovery is beginning to gain momentum, as seen by the number of large pharmas are already working with smaller AI-based biotechs. Though the term “AI” can carry certain mixed perceptions, scientists within pharma and biotech are starting to realize that AI is poised to make the human element more effective.